Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Among patients with bronchiectasis, once-daily treatment with brensocatib (10 mg or 25 mg) led to a lower annualized rate of pulmonary exacerbations than placebo, and the decline in FEV<sub>1</sub> was less with the 25-mg dose of brensocatib than with placebo. (Funded by Insmed; ASPEN ClinicalTrials.gov number, NCT04594369; EudraCT number, 2020-003688-25.).
Authors
- David Mauger
- Francesco Blasi (ORCID: https://orcid.org/0000-0002-2285-9970)
- Mark L. Metersky (ORCID: https://orcid.org/0000-0003-1968-1400)
- Michal Shteinberg (ORCID: https://orcid.org/0000-0002-0432-3398)
- Michael R. Loebinger (ORCID: https://orcid.org/0000-0002-5965-9913)
- Charles Haworth (ORCID: https://orcid.org/0000-0001-7126-2874)
- Charles L. Daley (ORCID: https://orcid.org/0000-0003-3324-926X)
- Felix C. Ringshausen (ORCID: https://orcid.org/0000-0001-9084-4968)
- James Duncan Chalmers (ORCID: https://orcid.org/0000-0001-5514-7868)
- Anthony De Soyza (ORCID: https://orcid.org/0000-0002-8566-0344)
- Ariel Teper
- Pierre‐Régis Burgel (ORCID: https://orcid.org/0000-0003-0903-9828)
- Pamela J. McShane (ORCID: https://orcid.org/0000-0003-1338-1407)
- Xiangmin Zhang (ORCID: https://orcid.org/0000-0001-9285-1619)
- M.D.C. Beato Zambrano
- Carlos Fernández
- Chunpeng Fan
- Kevin C. Mange
Institutions
- Pennsylvania State University (US)
- University of Connecticut (US)
- Inserm (FR)
- Technion – Israel Institute of Technology (IL)
- University of Dundee (GB)
- University of Milan (IT)
- Université Paris Cité (FR)
- University of Cambridge (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- National Jewish Health (US)
- Medizinische Hochschule Hannover (DE)
- Hôpital Cochin (FR)
- Royal Brompton Hospital (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Lung Institute (US)
- Papworth Hospital NHS Foundation Trust (GB)
- Insmed (United States) (US)
- Carmel Medical Center (IL)
- German Center for Lung Research (DE)
- NIHR Newcastle Biomedical Research Centre (GB)
- Institut Cochin (FR)
- Imperial College London (GB)
- Newcastle University (GB)
- The University of Texas Health Science Center at Tyler (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1056/nejmoa2411664
- Citations
- 97
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 147.28
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- University of Dundee
- Vertex Pharmaceuticals
- Insmed
- Deutsches Zentrum für Lungenforschung
- Grifols